6mm与10mm覆膜自膨式金属支架及塑料支架用于日本可切除或临界可切除胰腺癌伴远端胆道梗阻(STARDOM,JON-2402P):多中心随机对照试验研究方案
STARDOM试验为日本89家机构开展的多中心、开放标签、三臂优效性随机对照试验,计划纳入330例需术前胆道引流的可切除或临界可切除胰腺癌伴远端胆道梗阻成人患者,1:1:1随机分配至10mm覆膜自膨式金属支架(CSEMS)、塑料支架(PS,7Fr或8.5Fr)或6mm CSEMS组,主要终点为12周无事件生存比例。
要点
- 6mm CSEMS旨在平衡支架通畅性与不良事件风险。
- 主要终点为12周无支架相关事件生存比例。
- 随机分层因素包括机构、可切除性和胆囊切除史。
核心结论
- STARDOM试验旨在确定6mm CSEMS能否在可切除或临界可切除胰腺癌术前胆道引流中维持支架通畅并减少不良事件。
研究设计与样本
- 多中心、开放标签、三臂优效性随机对照试验,在日本89家机构开展,计划纳入330例成人患者。
- 纳入标准为可切除或临界可切除胰腺癌伴远端胆道梗阻需术前胆道引流,排除严重急性胆管炎或胃肠道梗阻患者。
- 按1:1:1随机分配至10mm CSEMS、PS(7Fr或8.5Fr)或6mm CSEMS组,按机构、可切除性和胆囊切除史分层。
主要发现
- 主要终点为12周无事件生存比例,事件包括复发性胆道梗阻、胰腺炎、胆囊炎、非闭塞性胆管炎、胃肠道出血、吸入性肺炎、肝脓肿、穿孔或死亡。
- 次要终点包括12周事件发生率、可切除和临界可切除患者12周和24周无事件生存比例及事件发生率、各主要终点组分比例及发生率、技术和临床成功、再干预成功及手术结局。
临床怎么用
- 若6mm CSEMS被证实可兼顾通畅性与安全性,可能优化术前胆道引流策略,保障新辅助化疗不间断并改善围手术期安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic cancer is one of the most lethal malignancies; patients with resectable (R) or borderline resectable (BR) disease are treated with neoadjuvant chemotherapy (NAC) followed by surgery. In those with distal biliary obstruction, preoperative biliary drainage enables the timely initiation and completion of NAC followed by surgery. The optimal stent type remains undetermined; 10-mm covered self-expandable metal stents (CSEMS) provide long patency but increase the risk of cholecystitis and pancreatitis, whereas plastic stents (PS) are safer but have shorter patency. A 6-mm CSEMS potentially offers a balanced option that reduces adverse events while maintaining patency during the preoperative period. The STARDOM trial is designed to determine whether 6-mm CSEMS can maintain stent patency while reducing adverse events in preoperative biliary drainage for R/BR pancreatic cancer with distal biliary obstruction. METHODS: In a multicenter, open-label, three-arm superiority randomized controlled trial at 89 institutions across Japan, including academic hospitals and high-volume referral centers, 330 adult patients (≥ 18 years) with R/BR pancreatic cancer and distal biliary obstruction requiring preoperative biliary drainage will be recruited by investigators at each participating institution and randomly assigned (1:1:1) to receive either a 10-mm CSEMS, PS (7Fr or 8.5Fr), or 6-mm CSEMS. Patients with severe acute cholangitis or gastrointestinal obstruction will be excluded. Randomization will be stratified by institution, resectability status, and history of cholecystectomy. The primary endpoint is the event-free survival proportion at 12 weeks, defined as the absence of stent-related events including recurrent biliary obstruction (RBO), pancreatitis, cholecystitis, non-occlusive cholangitis, gastrointestinal bleeding, aspiration pneumonia, liver abscess, perforation, or death. Secondary endpoints include the event incidence rate at 12 weeks, event-free survival proportion, and event incidence rate at 12 and 24 weeks in R and BR patients, respectively; the proportion and incidence rate of each primary endpoint component; technical and clinical success; re-intervention success; and surgical outcomes such as surgical resection proportion, operative time, blood loss, postoperative complications, hospital stay, R0 resection proportion, vascular invasion, and lymph node metastasis. DISCUSSION: The STARDOM trial is a nationwide multicenter randomized controlled study to directly compare 6-mm CSEMS with conventional 10-mm CSEMS and PS in the pancreatic cancer preoperative setting. Clarifying the optimal drainage method potentially improves perioperative safety, ensures uninterrupted NAC, and supports better oncosurgical outcomes in patients with R/BR pancreatic cancer. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT ID: jRCT1042250093; registered on August 9, 2025). Trial registry URL: https://jrct.mhlw.go.jp/latest-detail/jRCT1042250093 . First planned enrollment: August 25, 2025.
引用
- Yamashige D, Hijioka S, Yasuda I, et al. 6-mm versus 10-mm covered self-expandable metal stents and plastic stents for malignant distal biliary obstruction in resectable or borderline resectable pancreatic cancer in Japan (STARDOM, JON-2402P): study protocol for a multicenter randomized controlled trial. Trials. 2026. PMID: 42286634. doi:10.1186/s13063-026-09821-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。